Does Rallies show Form 4 insider transactions for SANA?

Yes. Rallies tracks SANA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SANA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SANA. It does not provide personalized investment advice.

SANA (Sana Biotechnology, Inc. Common Stock) Stock Analysis - Insider Trades

Sana Biotechnology, Inc. Common Stock (SANA) is a publicly traded Healthcare sector company. As of May 21, 2026, SANA trades at $3.11 with a market cap of $846.01M and a P/E ratio of -3.22. SANA moved +1.31% today. Year to date, SANA is -23.40%; over the trailing twelve months it is +48.80%. Its 52-week range spans $1.26 to $7.30. Analyst consensus is strong buy with an average price target of $10.17. Rallies surfaces SANA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SANA stock inside the company?

Recent SANA insider activity includes FMR LLC sold 100.00K, FMR LLC sold 25.00K, FMR LLC sold 164.91K, FMR LLC sold 1.00K, and Mulligan Richard sold 150.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SANA Key Metrics

Key financial metrics for SANA
Metric	Value
Price	$3.11
Market Cap	$846.01M
P/E Ratio	-3.22
EPS	$-0.96
Dividend Yield	0.00%
52-Week High	$7.30
52-Week Low	$1.26
Volume	1.09K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-244.17M
Gross Margin	0.00%

Recent SANA Insider Trades

FMR LLC sold 100.00K (~$611.00K) on Jan 8, 2025.
FMR LLC sold 25.00K (~$162.50K) on Jan 8, 2025.
FMR LLC sold 164.91K (~$1.11M) on Jan 8, 2025.
FMR LLC sold 1.00K (~$7.26K) on Jan 8, 2025.
Mulligan Richard sold 150.00K (~$583.17K) on Sep 25, 2024.

Latest SANA News

Sana Biotechnology Raises $69M via ATM Sale, Boosts Cash Runway to Mid-2027 — May 15, 2026
SG293 Preclinical Study Shows Dose-Dependent CAR T Expansion and Deep B Cell Depletion — May 12, 2026
Sana Biotechnology Secures $25M Mayo Clinic Investment and Advances SC451 Trial — May 11, 2026
Mayo Clinic Takes Equity Stake in Sana to Advance SC451 Therapy for Type 1 Diabetes — Apr 13, 2026
Sana Biotechnology Posts UP421 One-Year Success, Raises $133.7M, Plans SC451 IND — Mar 3, 2026

SANA Analyst Consensus

7 analysts cover SANA: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.17.

Common questions about SANA

Who is trading SANA stock inside the company?: Recent SANA insider activity includes FMR LLC sold 100.00K, FMR LLC sold 25.00K, FMR LLC sold 164.91K, FMR LLC sold 1.00K, and Mulligan Richard sold 150.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SANA?: Yes. Rallies tracks SANA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SANA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SANA. It does not provide personalized investment advice.